E2F3 and pachyonychia congenita: To identify E2F3 involved in PC progression, the prognostic role of E2F3 was analyzed via the GEPIA database, which showed that the overall survival rate (HR=1.5, p=0.063) and disease-free survival rate (HR=1.6, p=0.043) of PC patients with high expression of E2F3 were remarkably lower than those of low expression group (Figures 8A, B).